Candel Therapeutics financials
$10.88−2.77%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$26.7M | -$16.3M | -$15.8M | -$13.2M | -$11.2M | -$8.1M | -$8.1M | -$8.8M | -$8.6M | -$7.9M | -$10.3M | -$8.9M |
| Net income | -$38.9M | -$8.9M | -$29.5M | -$11.3M | -$4.8M | $7.4M | -$14.1M | -$10.6M | -$22.2M | -$8.2M | -$11.1M | -$8.4M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.52 | $-0.14 | $-0.58 | $-0.21 | $-0.09 | $0.13 | $-0.40 | $-0.33 | $-0.74 | $-0.28 | $-0.38 | $-0.29 |
| EBITDA | -$26.6M | -$16.1M | -$15.6M | -$13.0M | -$10.9M | -$7.9M | -$7.9M | -$8.5M | -$8.3M | -$7.7M | -$10.1M | -$8.6M |
| Operating cash flow | -$17.2M | -$18.0M | -$10.6M | -$10.2M | -$8.9M | -$8.6M | -$5.8M | -$6.6M | -$6.2M | -$8.4M | -$7.4M | -$8.8M |
| Free cash flow | -$17.3M | -$18.7M | -$11.0M | -$10.4M | -$8.9M | -$8.6M | -$5.8M | -$6.6M | -$6.2M | -$8.4M | -$7.5M | -$8.9M |
| Diluted shares | 74.1M | 62.4M | 50.7M | 54.9M | 51.5M | 54.8M | 35.6M | 32.0M | 29.9M | 29.2M | 29.0M | 28.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $201.6M | $194.8M | $119.7M | $87.0M | $100.7M | $92.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $47.8M | $47.5M | $47.1M | $5.2M | $7.6M | $10.1M |
| Total assets | $208.1M | $201.9M | $125.2M | $93.6M | $106.0M | $95.9M |
| Total liabilities | $82.0M | $63.9M | $73.3M | $13.5M | $15.8M | $21.2M |
| Shareholders' equity | $126.1M | $138.0M | $51.9M | $80.1M | $90.2M | $74.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology